Middle East Pharmaceutical Industries Company
4016
Rank in Stocks
#11227
Middle East Pharmaceutical Industries Company (MEPIC), established in Riyadh,... Middle East Pharmaceutical Industries Company (MEPIC), established in Riyadh, Saudi Arabia, in 1998, is a global pharmaceutical entity. The company's core activities encompass the entire lifecycle of generic medicines and various pharmaceutical products, from research and development to manufacturing and sales, catering to both local and international markets. Its business operations are strategically divided into private sector, public sector, and export divisions. MEPIC offers an extensive array of products designed to address a wide range of medical conditions. This includes dermatological treatments, remedies for respiratory ailments, central nervous system disorders, digestive issues, and musculoskeletal complaints, alongside medications for the urinary and reproductive systems. Furthermore, the company provides disinfectants and a diverse portfolio of therapeutic agents covering areas such as sexual health, diabetes, cardiovascular diseases, anti-infectives, anti-parasitics, pain relief, antiseptics, and general men's and women's health. These pharmaceutical and health products are supplied in numerous formats, including creams, ointments, syrups, capsules, tablets, gels, lotions, sprays, topical solutions, and personal hygiene items like hand sanitizers, mouthwashes, and soaps. In addition to its proprietary product lines, MEPIC leverages its manufacturing capabilities to offer contract manufacturing services. The company also specializes in cosmetic products, general health aids, and nutritional supplements. Originally known as Middle East Chemical Products Factory Company, the organization officially rebranded to Middle East Pharmaceutical Industries Company in January 2006.
Share Price
$16.86
Last synced: 2026-11-11
Market Cap
$591.24M
Change (1 day)
0.08%
Change (1 year)
-10.27%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Middle East Pharmaceutical Industries Company (4016)
Category
Healthcare
EPS for Middle East Pharmaceutical Industries Company (4016)
EPS as of September 2026 TTM: $0.88
According to Middle East Pharmaceutical Industries Company's latest financial reports, its current EPS (TTM) is $0.88. At the end of 2025 the company had an EPS of $0.74, an increase over its 2024 EPS of $0.61.
EPS history for Middle East Pharmaceutical Industries Company from 2019 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.88 | 18.81% |
| 2025 | $0.74 | 21.70% |
| 2024 | $0.61 | 21.04% |
| 2023 | $0.50 | 11.05% |
| 2022 | $0.45 | -10.38% |
| 2021 | $0.50 | -9.13% |
| 2020 | $0.55 | 34.79% |
| 2019 | $0.41 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $1.69 | 92.22% |
US
|
|
| $1.93 | 119.61% |
SE
|
|
| $6.91 | 686.40% |
FR
|
|
| $0.02 | -97.78% |
HK
|
|
| $2.71 | 208.21% |
IT
|
Questions about Middle East Pharmaceutical Industries Company's earnings per share (EPS)
What is Middle East Pharmaceutical Industries Company's earnings per share (EPS)?
Middle East Pharmaceutical Industries Company's earnings per share (EPS) over the last twelve months is $0.88, as of Sep 2026.
What was Middle East Pharmaceutical Industries Company's earnings per share (EPS) in 2025?
In 2025, Middle East Pharmaceutical Industries Company's earnings per share (EPS) was $0.74, 21.31% more than in 2024 ($0.61).
How has Middle East Pharmaceutical Industries Company's earnings per share (EPS) changed since 2020?
From 2020 to 2025, Middle East Pharmaceutical Industries Company's earnings per share (EPS) went from $0.55 to $0.74, an average growth of 6.11% a year.
How does Middle East Pharmaceutical Industries Company's earnings per share (EPS) compare with similar companies?
Middle East Pharmaceutical Industries Company's earnings per share (EPS) ($0.88) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Ipsen S.A., with $6.91.